Steve Alas
Impact in
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 3
- Cytokine Signaling Pathways and Interactions 2
-
- Immune Cell Function and Interaction 2
- Toxin Mechanisms and Immunotoxins 1
- Co-authors
- Benjamin Bonavida (6 shared papers)Christos Emmanouilides (2 shared papers)Nabil Hanna (1 shared paper)Tammy Lam (1 shared paper)Aïcha Demidem (1 shared paper)Kandasamy Hariharan (1 shared paper)L. David Finger (1 shared paper)Junzhuan Qiu (1 shared paper)
- Journals
- BioEssays (1 paper)Cancer Biotherapy and Radiopharmaceuticals (1 paper)PubMed (5 papers)
- Partner nations
- United States
In The Last Decade
Steve Alas
7 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 77
- Genetics 355
- Pathology and Forensic Medicine 573
- Oncology 477
- Immunology 281
- Radiology, Nuclear Medicine and Imaging 230
Countries citing papers authored by Steve Alas
This map shows the geographic impact of Steve Alas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Alas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Alas more than expected).
Fields of papers citing papers by Steve Alas
This network shows the impact of papers produced by Steve Alas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Alas. The network helps show where Steve Alas may publish in the future.
Co-authors
The 12 scholars most cited alongside Steve Alas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1997 | 328 | |
| 2 | Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. | 2001 | 244 |
| 3 | Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. | 2001 | 231 |
| 4 | Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. | 2003 | 198 |
| 5 | 2005 | 123 | |
| 6 | Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. | 2002 | 75 |
| 7 | Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. | 2000 | 58 |
About Steve Alas
Steve Alas is a scholar working on Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 7 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Immune Cell Function and Interaction (2 papers), DNA Repair Mechanisms (1 paper), NF-κB Signaling Pathways (1 paper), Lymphoma Diagnosis and Treatment (1 paper), Toxin Mechanisms and Immunotoxins (1 paper) and CRISPR and Genetic Engineering (1 paper). The work is most often cited by research in Genetics (355 citations), Pathology and Forensic Medicine (573 citations), Oncology (477 citations), Immunology (281 citations) and Radiology, Nuclear Medicine and Imaging (230 citations). Steve Alas has collaborated with scholars based in United States. Frequent co-authors include Benjamin Bonavida, Christos Emmanouilides, Nabil Hanna, Tammy Lam, Aïcha Demidem, Kandasamy Hariharan, L. David Finger, Junzhuan Qiu, Binghui Shen and Li Zheng. Their work appears in journals such as BioEssays, Cancer Biotherapy and Radiopharmaceuticals and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.